These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12893398)

  • 1. Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor.
    Grover SA; Coupal L; Zowall H; Weiss TW; Alexander CM
    Am J Med; 2003 Aug; 115(2):122-8. PubMed ID: 12893398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?
    Grover SA; Coupal L; Zowall H; Dorais M
    Circulation; 2000 Aug; 102(7):722-7. PubMed ID: 10942738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
    Grover SA; Coupal L; Kaouache M; Lowensteyn I
    Can J Cardiol; 2007 May; 23(6):467-73. PubMed ID: 17487292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia as a risk factor at elderly age.
    Wenger NK
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):4-9. PubMed ID: 15133423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
    Lee VW; Ho IC; Chan WS; Tam KY; Lee KK
    Am J Cardiovasc Drugs; 2008; 8(3):199-205. PubMed ID: 18533740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
    Grover SA; Coupal L; Zowall H; Alexander CM; Weiss TW; Gomes DR
    Diabetes Care; 2001 Jan; 24(1):45-50. PubMed ID: 11194239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors.
    Breuker C; Clement F; Mura T; Macioce V; Castet-Nicolas A; Audurier Y; Boegner C; Morcrette E; Jalabert A; Villiet M; Avignon A; Sultan A
    Int J Cardiol; 2018 Oct; 268():195-199. PubMed ID: 30041785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic population aged ≥ 65 years by lipid-lowering medication use status.
    Candrilli SD; Kuznik A; Mendys PM; Wilson DJ
    Postgrad Med; 2010 Sep; 122(5):142-9. PubMed ID: 20861598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin Prescribing Patterns: An Analysis of Data From Patients With Diabetes in the National Hospital Ambulatory Medical Care Survey Outpatient Department and National Ambulatory Medical Care Survey Databases, 2005-2010.
    Pauff BR; Jiroutek MR; Holland MA; Sutton BS
    Clin Ther; 2015 Jun; 37(6):1329-39. PubMed ID: 25869626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein cholesterol level and statin use among Medicare beneficiaries with diabetes mellitus.
    Qualls LG; Hammill BG; Maciejewski ML; Curtis LH; Jones WS
    Diab Vasc Dis Res; 2016 May; 13(3):244-6. PubMed ID: 26802221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H; Kamal-Bahl S; Wong ND
    Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of lipid disorders in the elderly.
    Playford DA; Watts GF
    Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutrition-related cardiovascular risk factors in older people: results from the Third National Health and Nutrition Examination Survey.
    Erlinger TP; Pollack H; Appel LJ
    J Am Geriatr Soc; 2000 Nov; 48(11):1486-9. PubMed ID: 11083329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.